

# Almer M Van Der Sloot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7204542/publications.pdf>

Version: 2024-02-01

31  
papers

1,148  
citations

394286

19  
h-index

434063

31  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1765  
citing authors

#	ARTICLE	IF	CITATIONS
1	Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8634-8639.	3.3	151
2	Computational design of peptide ligands. Trends in Biotechnology, 2011, 29, 231-239.	4.9	146
3	RET-Familial Medullary Thyroid Carcinoma Mutants Y791F and S891A Activate a Src/JAK/STAT3 Pathway, Independent of Glial Cell Line-Derived Neurotrophic Factor. Cancer Research, 2005, 65, 1729-1737.	0.4	84
4	A novel classification system to predict the pathogenic effects of CHD7 missense variants in CHARGE syndrome. Human Mutation, 2012, 33, 1251-1260.	1.1	65
5	Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death and Disease, 2010, 1, e83-e83.	2.7	63
6	Engineering of weak helper interactions for high-efficiency FRET probes. Nature Methods, 2013, 10, 1021-1027.	9.0	62
7	A Novel Genetic Selection System for Improved Enantioselectivity of <i>Bacillus subtilis</i> Lipase A. ChemBioChem, 2008, 9, 1110-1115.	1.3	60
8	DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design. Journal of Biological Chemistry, 2008, 283, 20560-20568.	1.6	56
9	Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants. Genetics in Medicine, 2018, 20, 872-881.	1.1	38
10	Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development. Genetics, 2020, 214, 1103-1120.	1.2	36
11	Loop Grafting of <i>Bacillus subtilis</i> Lipase A: Inversion of Enantioselectivity. Chemistry and Biology, 2008, 15, 782-789.	6.2	35
12	Protein design with fragment databases. Current Opinion in Structural Biology, 2011, 21, 452-459.	2.6	32
13	An improved understanding of TNFL/TNFR interactions using structure-based classifications. Trends in Biochemical Sciences, 2012, 37, 353-363.	3.7	31
14	Stabilization of TRAIL, an all- $\alpha$ -sheet multimeric protein, using computational redesign. Protein Engineering, Design and Selection, 2004, 17, 673-680.	1.0	30
15	Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase toward Its Death Receptors. Biochemistry, 2009, 48, 2180-2191.	1.2	29
16	Building blocks for protein interaction devices. Nucleic Acids Research, 2010, 38, 2645-2662.	6.5	28
17	Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL. Molecular and Cellular Proteomics, 2012, 11, M111.013730.	2.5	25
18	Protein design in biological networks: from manipulating the input to modifying the output. Protein Engineering, Design and Selection, 2009, 22, 537-542.	1.0	24

#	ARTICLE	IF	CITATIONS
19	Binding of phage displayed Bacillus subtilis lipase A to a phosphonate suicide inhibitor. Journal of Biotechnology, 2003, 101, 19-28.	1.9	22
20	Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality. Journal of Cell Biology, 2020, 219, .	2.3	20
21	Mutational Analysis of a Key Residue in the Substrate Specificity of a Cephalosporin Acylase. ChemBioChem, 2004, 5, 820-825.	1.3	19
22	Targeting AML through DR4 with a novel variant of rhTRAIL. Journal of Cellular and Molecular Medicine, 2011, 15, 2216-2231.	1.6	18
23	Identification and optimization of molecular glue compounds that inhibit a noncovalent E2 enzymeâ€“ubiquitin complex. Science Advances, 2021, 7, eabi5797.	4.7	17
24	At Long Last, a C-Terminal Bookend for the Ubiquitin Code. Molecular Cell, 2018, 70, 568-571.	4.5	11
25	RGD-avidinâ€“biotin pretargeting to $\alpha_5\beta_3$ integrin enhances the proapoptotic activity of TNF-related apoptosis inducing ligand (TRAIL). Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 225-235.	2.2	10
26	Generation of rationally-designed nerve growth factor (NGF) variants with receptor specificity. Biochemical and Biophysical Research Communications, 2018, 495, 700-705.	1.0	9
27	The Design and Characterization of Receptor-selective APRIL Variants*. Journal of Biological Chemistry, 2012, 287, 37434-37446.	1.6	8
28	Synthetic Genomics: Rewriting the Genome Chromosome by Chromosome. Molecular Cell, 2017, 66, 441-443.	4.5	7
29	T-RMSD: A Fine-grained, Structure-based Classification Method and its Application to the Functional Characterization of TNF Receptors. Journal of Molecular Biology, 2010, 400, 605-617.	2.0	5
30	A novel CHD7 mutation in an adolescent presenting with growth and pubertal delay. Annals of Pediatric Endocrinology and Metabolism, 2019, 24, 49-54.	0.8	5
31	Computational Design of TNF Ligand-Based Protein Therapeutics. Advances in Experimental Medicine and Biology, 2011, 691, 521-534.	0.8	2